drugset / Trial / NCT06544655
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
Timeline
- Start
- 2024-10-10
- Primary completion
- 2027-10-14
- Completion
- 2027-10-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986484 | Unknown | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |